Biology-Guided Radiation Therapy An Evolving Treatment Paradigm

被引:5
作者
Ladbury, Colton [1 ]
Eustace, Nicholas [1 ]
Amini, Arya [1 ]
Dandapani, Savita [1 ]
Williams, Terence [1 ]
机构
[1] City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 East Duarte Rd, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
PET; Radiotherapy; BgRT; Biology-guided radiotherapy; lung cancer; lymphoma; gastrointestinal cancer; molecular imaging; CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; HODGKIN-LYMPHOMA; FDG-PET; INTERNATIONAL WORKSHOP; RESPONSE ASSESSMENT; BULKY DISEASE; OPEN-LABEL; RADIOTHERAPY; CRITERIA;
D O I
10.1016/j.soc.2023.02.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In radiation oncology, imaging guides patient selection, treatment volume delineation, and accurate treatment delivery. Therefore, improvements in radiotherapy delivery are intrinsically linked to advances in imaging technology. The advent of 3D-radiotherapy was made possible by computed tomography (CT)-based radiation treatment plan-ning, and more recently, novel magnetic resonance-guided radiation treatment has provided increasing soft tissue resolution to enable more precise anatomic target-ing.1,2 Advances in functional imaging modalities such as PET have demonstrated promise for further informing radiotherapy delivery by providing risk stratification and a means of gauging treatment response via correlation with biological activity. Indeed, early studies assessing the incorporation of PET into radiation treatment plan-ning suggested improved radiation planning (eg, incorporation of CT-subclinical dis-ease) and outcomes when combining PET with radiation.3-5 This has led to the concept of biology-guided radiotherapy (BgRT), an emerging external beam radiotherapy treatment paradigm that uses biological/molecular imaging to inform ra- diation treatment. A primary way of BgRT functions is by using imaging as a biomarker that is both prognostic and predictive of response to therapy. PET imaging is the most common modality, with the associated radiotracer being used to characterize relevant treat- ment metrics such as tumor burden/distribution, hypoxia, angiogenesis, metabolism, and proliferation.6 Functional imaging like PET can provide relevant information at several points in the radiation delivery process: before and following treatment as a prognostic indicator, as an indicator of response to therapy, during radiation to inform treatment planning and adaptation. Radiation therapy is at the cusp of integrating advanced functional imaging and treatment delivery systems and is poised to use biological information afforded by mo- lecular imaging during BgRT to deliver more effective therapies. This potentially will enable treatment of multiple disease sites simultaneously, improve motion manage- ment, decrease treatment margins, and optimize targeting of biologically active tumor. This review highlights prior applications of PET imaging to prognosticate patients and guide radiation treatment, which will be relevant as integrated BgRT develops. A sum- mary of included studies is summarized in Table 1.
引用
收藏
页码:553 / 568
页数:16
相关论文
共 43 条
[1]  
Ballinger J, 2022, PET CT IMAGING, V18, P27
[2]  
Borchmann P, 2021, LANCET ONCOL, V22, P223, DOI 10.1016/S1470-2045(20)30601-X
[3]   Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer [J].
Bradley, Jeffrey D. ;
Hu, Chen ;
Komaki, Ritsuko R. ;
Masters, Gregory A. ;
Blumenschein, George R. ;
Schild, Steven E. ;
Bogart, Jeffrey A. ;
Forster, Kenneth M. ;
Magliocco, Anthony M. ;
Kavadi, Vivek S. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Clifford G. ;
Wynn, Raymond B. ;
Koprowski, Christopher D. ;
Olson, Michael R. ;
Meng, Joanne ;
Paulus, Rebecca ;
Curran, Walter J., Jr. ;
Choy, Hak .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) :706-+
[4]   Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].
Bradley, Jeffrey D. ;
Paulus, Rebecca ;
Komaki, Ritsuko ;
Masters, Gregory ;
Blumenschein, George ;
Schild, Steven ;
Bogart, Jeffrey ;
Hu, Chen ;
Forster, Kenneth ;
Magliocco, Anthony ;
Kavadi, Vivek ;
Garces, Yolanda I. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Cliff ;
Wynn, Raymond B. ;
Koprowski, Christopher ;
Meng, Joanne ;
Beitler, Jonathan ;
Gaur, Rakesh ;
Curran, Walter, Jr. ;
Choy, Hak .
LANCET ONCOLOGY, 2015, 16 (02) :187-199
[5]   Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma [J].
Ceriani, Luca ;
Martelli, Maurizio ;
Gospodarowicz, Maria K. ;
Ricardi, Umberto ;
Ferreri, Andres J. M. ;
Chiappella, Annalisa ;
Stelitano, Caterina ;
Balzarotti, Monica ;
Cabrera, Maria E. ;
Cunningham, David ;
Guarini, Attilio ;
Zinzani, Pier Luigi ;
Giovanella, Luca ;
Johnson, Peter W. M. ;
Zucca, Emanuele .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (01) :42-49
[6]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[7]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[8]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[9]  
Cooke S, 2020, RADIOTHER ONCOL, V152, pS345
[10]   FDG-PET/CT in the evaluation of anal carcinoma [J].
Cotter, Shane E. ;
Grigsby, Perry W. ;
Siegel, Barry A. ;
Dehdashti, Farrokh ;
Malyapa, Robert S. ;
Fleshman, James W. ;
Birnbaum, Elisa H. ;
Wang, Xia ;
Abbey, Elliot ;
Tan, Benjamin ;
Kodner, Ira J. ;
Hunt, Steven R. ;
Lowney, Jennifer K. ;
Mutch, Matthew G. ;
Dietz, David W. ;
Myerson, Robert J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03) :720-725